1. Home
  2. GMAB
  3. GMAB News

Latest Genmab A/S ADS (GMAB) News on September 18, 2025

Genmab A/S (GMAB) Scores FDA Breakthrough for Rina-S
GMAB

Insider Monkey

7 days ago

Genmab A/S (GMAB) Scores FDA Breakthrough for Rina-S

Genmab (CPSE:GMAB) Is Up 10.3% After FDA Breakthrough for Rina-S in Endometrial Cancer – Has The Bull Case Changed?
GMAB

Simply Wall St.

12 days ago

Genmab (CPSE:GMAB) Is Up 10.3% After FDA Breakthrough for Rina-S in Endometrial Cancer – Has The Bull Case Changed?

AbbVie and Genmab’s Epkinly shows outpatient viability in Phase II trial
GMAB

Clinical Trials Arena

14 days ago

AbbVie and Genmab’s Epkinly shows outpatient viability in Phase II trial

GMAB

MT Newswires

15 days ago

Genmab Says Outpatient Epcoritamab Treatment Feasible in Phase 2 Study

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
GMAB

Business Wire

15 days ago

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Genmab A/S (GMAB)’s Epcoritamab Delivers 95% Response in Lymphoma
GMAB

Insider Monkey

20 days ago

Genmab A/S (GMAB)’s Epcoritamab Delivers 95% Response in Lymphoma

Genmab A/S (GMAB) Expands Tivdak and Epkinly Commercial Push Globally
GMAB

Insider Monkey

20 days ago

Genmab A/S (GMAB) Expands Tivdak and Epkinly Commercial Push Globally

ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial
GMAB

Insider Monkey

20 days ago

ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial

ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth
GMAB

Zacks

a month ago

ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth

SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors
GMAB

GlobeNewswire

a month ago

SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors

Capital Increase in Genmab as a Result of Employee Warrant Exercise
GMAB

GlobeNewswire

a month ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

William Blair Remains Bullish on Genmab A/S (GMAB)
GMAB

Insider Monkey

a month ago

William Blair Remains Bullish on Genmab A/S (GMAB)

iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments
GMAB

PR Newswire

2 months ago

iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments

Genmab (GMAB) Upgraded to Strong Buy: Here's Why
GMAB

Zacks

2 months ago

Genmab (GMAB) Upgraded to Strong Buy: Here's Why

Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?
GMAB

Zacks

2 months ago

Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

3 months ago

Transactions in Connection with Share Buy-back Program

Capital Increase in Genmab as a Result of Employee Warrant Exercise
GMAB

GlobeNewswire

3 months ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
GMAB

GlobeNewswire

3 months ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

3 months ago

Transactions in Connection with Share Buy-back Program

Genmab announces Phase Ib/II trial outcomes of epcoritamab combo for DLBCL
GMAB

Clinical Trials Arena

3 months ago

Genmab announces Phase Ib/II trial outcomes of epcoritamab combo for DLBCL

GMAB

MT Newswires

3 months ago

Genmab Says Experimental Combination Trial Shows High Response Rates in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
GMAB

GlobeNewswire

3 months ago

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Grant of Restricted Stock Units and Warrants to Employees in Genmab
GMAB

GlobeNewswire

3 months ago

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

3 months ago

Transactions in Connection with Share Buy-back Program

ASCO25: Genmab’s Rina-S en route to ‘blockbuster potential’ amid further positive data
GMAB

Pharmaceutical Technology

3 months ago

ASCO25: Genmab’s Rina-S en route to ‘blockbuster potential’ amid further positive data

Why Genmab Stock Smashed It on Monday
GMAB

Motley Fool

4 months ago

Why Genmab Stock Smashed It on Monday

GMAB

MT Newswires

4 months ago

Genmab Says New Trial Data Shows 'Encouraging Anti-Tumor Activity' for Rinatabart Sesutecan

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
GMAB

GlobeNewswire

4 months ago

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

4 months ago

Transactions in Connection with Share Buy-back Program

GMAB

Morningstar Research

4 months ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital
GMAB

TipRanks

4 months ago

Genmab price target lowered to DKK 2,000 from DKK 2,300 at RBC Capital

GMAB

MT Newswires

4 months ago

RBC Cuts Price Target on Genmab to DKK2,000 From DKK2,300, Keeps Outperform Rating

Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference
GMAB

GlobeNewswire

4 months ago

Genmab to Participate in a Fireside Chat at the 46th Goldman Sachs Annual Global Healthcare Conference

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

4 months ago

Transactions in Connection with Share Buy-back Program

Genmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025
GMAB

Insider Monkey

4 months ago

Genmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO 2025

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GMAB

GlobeNewswire

4 months ago

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference
GMAB

GlobeNewswire

4 months ago

Genmab to Participate in a Fireside Chat at the 2025 Jefferies Global Health Care Conference

Capital Increase in Genmab as a Result of Employee Warrant Exercise
GMAB

GlobeNewswire

4 months ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

4 months ago

Transactions in Connection with Share Buy-back Program

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress
GMAB

GlobeNewswire

4 months ago

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

4 months ago

Transactions in Connection with Share Buy-back Program

Genmab AS (GMAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives
GMAB

GuruFocus.com

4 months ago

Genmab AS (GMAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives

GMAB

MT Newswires

4 months ago

Genmab Q1 Earnings, Revenue Increase

Genmab Announces Financial Results for the First Quarter of 2024
GMAB

GlobeNewswire

4 months ago

Genmab Announces Financial Results for the First Quarter of 2024

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

4 months ago

Transactions in Connection with Share Buy-back Program

GMAB

MT Newswires

5 months ago

Sector Update: Health Care Stocks Rise Premarket Friday

GMAB

MT Newswires

5 months ago

Genmab to Seek FDA Review of Follicular Lymphoma Combination Therapy

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
GMAB

Business Wire

5 months ago

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Is Genmab A/S (GMAB) the Most Profitable Growth Stock to Buy Now?
GMAB

Insider Monkey

5 months ago

Is Genmab A/S (GMAB) the Most Profitable Growth Stock to Buy Now?

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

5 months ago

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

5 months ago

Transactions in Connection with Share Buy-back Program

GMAB or RGEN: Which Is the Better Value Stock Right Now?
GMAB

Zacks

5 months ago

GMAB or RGEN: Which Is the Better Value Stock Right Now?

Should Value Investors Buy Genmab (GMAB) Stock?
GMAB

Zacks

5 months ago

Should Value Investors Buy Genmab (GMAB) Stock?

Genmab (CPSE:GMAB) Reports US$3 Billion DARZALEX Sales For Q1 2025
GMAB

Simply Wall St.

5 months ago

Genmab (CPSE:GMAB) Reports US$3 Billion DARZALEX Sales For Q1 2025

GMAB

MT Newswires

5 months ago

Genmab Says Darzalex Q1 Global Net Sales Reach $3.24 Billion

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
GMAB

GlobeNewswire

5 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Transactions in Connection with Share Buy-back Program
GMAB

GlobeNewswire

5 months ago

Transactions in Connection with Share Buy-back Program

Genmab A/S Share Capital Reduction
GMAB

GlobeNewswire

5 months ago

Genmab A/S Share Capital Reduction

Transactions In Connection with Share Buy-back Program
GMAB

GlobeNewswire

5 months ago

Transactions In Connection with Share Buy-back Program

Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?
GMAB

Insider Monkey

6 months ago

Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
GMAB

GlobeNewswire

6 months ago

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Is Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts?
GMAB

Insider Monkey

6 months ago

Is Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts?

GMAB

MT Newswires

6 months ago

Genmab Says European Commission Grants Marketing Authorization for Tivdak as Cervical Cancer Treatment

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
GMAB

Business Wire

6 months ago

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Transactions in connection with share buy-back program
GMAB

GlobeNewswire

6 months ago

Transactions in connection with share buy-back program

Genmab’s Tivdak approved in Japan for advanced cervical cancer
GMAB

Pharmaceutical Technology

6 months ago

Genmab’s Tivdak approved in Japan for advanced cervical cancer

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
GMAB

Benzinga

6 months ago

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

GMAB

MT Newswires

6 months ago

Genmab Says Japan Approves Tivdak for Cervical Cancer

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
GMAB

Business Wire

6 months ago

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Genmab Announces Initiation of Share Buy-Back Program
GMAB

GlobeNewswire

6 months ago

Genmab Announces Initiation of Share Buy-Back Program

GMAB

MT Newswires

6 months ago

Genmab Denies Trade Secret Misappropriation Claims by AbbVie

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.
GMAB

GlobeNewswire

6 months ago

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Genmab A/S (GMAB): A Bull Case Theory
GMAB

Insider Monkey

6 months ago

Genmab A/S (GMAB): A Bull Case Theory

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
GMAB

GlobeNewswire

6 months ago

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
GMAB

GlobeNewswire

6 months ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
GMAB

GlobeNewswire

6 months ago

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Passing of Genmab A/S’ Annual General Meeting
GMAB

GlobeNewswire

6 months ago

Passing of Genmab A/S’ Annual General Meeting

A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV
GMAB

BioPharma Dive

6 months ago

A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV

Genmab says J&J not exercising option on HexaBody-CD38
GMAB

TipRanks

6 months ago

Genmab says J&J not exercising option on HexaBody-CD38

GMAB

MT Newswires

6 months ago

William Blair Upgrades Genmab to Outperform From Market Perform

GMAB

Investing.com

6 months ago

Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded

GMAB

MT Newswires

6 months ago

RBC Cuts Price Target on Genmab to DKK2,300 From DKK2,400, Keeps Outperform Rating

GMAB

MT Newswires

6 months ago

Truist Lowers Price Target on Genmab to $45 From $50, Maintains Buy Rating

GMAB

MT Newswires

6 months ago

Genmab Says Johnson & Johnson Declines Global License Option for HexaBody-CD38; Shares Fall

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
GMAB

Business Wire

6 months ago

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Is Genmab A/S (GMAB) the Best Cash-Rich Undervalued Stock to Invest In?
GMAB

Insider Monkey

6 months ago

Is Genmab A/S (GMAB) the Best Cash-Rich Undervalued Stock to Invest In?

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
GMAB

GlobeNewswire

6 months ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
GMAB

GlobeNewswire

7 months ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
GMAB

GlobeNewswire

7 months ago

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

Genmab A/S (GMAB): Among the Stocks That Will Go to the Moon According to Analysts
GMAB

Insider Monkey

7 months ago

Genmab A/S (GMAB): Among the Stocks That Will Go to the Moon According to Analysts

Capital Increase in Genmab as a Result of Employee Warrant Exercise
GMAB

GlobeNewswire

7 months ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Is Genmab (GMAB) One of the Best Growth Stocks to Invest In According to Analysts?
GMAB

Insider Monkey

7 months ago

Is Genmab (GMAB) One of the Best Growth Stocks to Invest In According to Analysts?

GMAB

MT Newswires

7 months ago

Genmab Gets Japanese Regulatory Approval for Follicular Lymphoma Drug

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
GMAB

GlobeNewswire

7 months ago

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference
GMAB

GlobeNewswire

7 months ago

Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference

Why Genmab (GMAB) and Sonic Automotive (SAH) Are Advancing Today
GMAB

Insider Monkey

7 months ago

Why Genmab (GMAB) and Sonic Automotive (SAH) Are Advancing Today

GMAB

MT Newswires

7 months ago

Leerink Upgrades Genmab to Outperform From Market Perform, Price Target is $27

Notice to Convene the Annual General Meeting of Genmab A/S
GMAB

GlobeNewswire

7 months ago

Notice to Convene the Annual General Meeting of Genmab A/S

Genmab AS (GMAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...
GMAB

GuruFocus.com

7 months ago

Genmab AS (GMAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...

Genmab Files Annual Report with the U.S. Securities and Exchange Commission
GMAB

GlobeNewswire

7 months ago

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

Share on Social Networks: